Evidence map›Paper›PMID 34359580›Full record

ArticleCancers2021

Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma.

Mengshi Li, Dijie Liu, Dongyoul Lee, Yinwen Cheng, Nicholas J Baumhover, Brenna M Marks, Edwin A Sagastume, Zuhair K Ballas, Frances L Johnson, Zachary S Morris and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Combination therapy of anEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. EJNMMI radiopharmacy and chemistry · 2025
    Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Mengshi LiViewpoint Molecular Targeting, Inc., Coralville, IA 52241, USA.ORCID 0000-0003-3398-0183
Dijie LiuViewpoint Molecular Targeting, Inc., Coralville, IA 52241, USA.
Dongyoul LeeDepartment of Radiology, University of Iowa, Iowa City, IA 52242, USA.
Yinwen ChengInterdisciplinary Graduate Program in Human Toxicology, University of Iowa, Iowa City, IA 52242, USA.
Nicholas J BaumhoverViewpoint Molecular Targeting, Inc., Coralville, IA 52241, USA.
Brenna M MarksViewpoint Molecular Targeting, Inc., Coralville, IA 52241, USA.
Edwin A SagastumeViewpoint Molecular Targeting, Inc., Coralville, IA 52241, USA.
Zuhair K BallasDepartment of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA.ORCID 0000-0001-5569-1230
Frances L JohnsonViewpoint Molecular Targeting, Inc., Coralville, IA 52241, USA.
Zachary S MorrisDepartment of Human Oncology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA.
Michael K SchultzViewpoint Molecular Targeting, Inc., Coralville, IA 52241, USA.
University of Iowa · USViewpoint Molecular Targeting (United States) · USUniversity of Wisconsin–Madison · US

Funding

Small Business Innovation Research 1R43CA232954-01A1
6 · The paper itself

Abstract

Radiotherapy can facilitate the immune recognition of immunologically "cold" tumors and enhance the efficacy of anti-PD-1 and anti-CTLA-4 immune checkpoint inhibitors (ICIs) in melanoma. Systemic administration of receptor-targeted radionuclide therapy has the potential to selectively deliver radionuclides to multiple tumors throughout the body in metastatic settings. By triggering immunologic cell death and increasing the immune susceptibility of surviving tumor cells in these locations, targeted radionuclide therapies may overcome resistance to ICIs and render immunologically "cold" tumors throughout the body responsive to ICIs and immunologically "hot". Here, we show the anti-tumor cooperation of targeted α-particle radionuclide therapy (α-TRT) and ICIs in preclinical models of melanoma. Melanocortin 1 receptor (MC1R)-targeted radiopeptide [

Indexed as

alpha-particle radiotherapyimmune checkpoint inhibitorsimmunogenic cell deathimmunotherapymelanoma

Identifiers

PMID34359580
PMCPMC8345035
OpenAlexW3184790238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.